Evaluation of Androgen Receptor in Relation to Estrogen Receptor (AR/ER) and Progesterone Receptor (AR/PgR): A New Must in Breast Cancer?

Table 2

Impact of AR/ER, AR/PgR, and ER/PgR ratios on OS in primary tumors of luminal BC patients (no. 89).

	Median ratios (range)
AR/ER	0.95 (0.06 - 95.00)
AR/PgR	1.55 (0.06 - 95.00)
ER/PgR	1.60 (0.08 - 90.00)
OS according to best cut-off ratio
Median follow-up: 78 months (range 7 - 155)
	no. deaths/no. patients	Median OS (months); (95% CI)	HR; (95% CI)	p
Overall	55/89	63 (46-76)	-	-
AR/ER
<0.95	28/47	64 (41-82)	1.00
≥0.95	27/42	60 (42-83)	1.05 (0.62-1.78)	0.861
AR/PgR
<1.54	21/39	82 (65-89)	1.00
≥1.54	34/50	42 (34-56)	2.27 (1.30-3.97)	0.004
ER/PgR
<2.00	25/40	82 (62-88)	1.00
≥2.00	30/49	42 (34-64)	1.89 (1.10-3.24)	0.021

AR, androgen receptor; ER, estrogen receptor; PgR, progesterone receptor; OS, overall survival; HR, hazard ratio; CI, confidence interval; ND, not determinable; NR, not reached.